Cargando…

Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tianyu, Tang, Xiaofang, Song, Ying, Yao, Yi, Zhao, Xueyan, Gao, Zhan, Yang, Yuejin, Gao, Runlin, Xu, Bo, Yuan, Jinqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719473/
https://www.ncbi.nlm.nih.gov/pubmed/35141130
http://dx.doi.org/10.5334/gh.812
_version_ 1784624942796505088
author Li, Tianyu
Tang, Xiaofang
Song, Ying
Yao, Yi
Zhao, Xueyan
Gao, Zhan
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
author_facet Li, Tianyu
Tang, Xiaofang
Song, Ying
Yao, Yi
Zhao, Xueyan
Gao, Zhan
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
author_sort Li, Tianyu
collection PubMed
description BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-world clinical practice and to assess the effect of GDPM on clinical outcomes. DESIGN: A retrospective cohort study. METHODS: Consecutive patients admitted to Fuwai Hospital between January 2013 and December 2013 were recruited. GDPM comprised aspirin, clopidogrel, statins, β-blockers, and angiotensin-converting enzyme inhibitors/angiotensin Ⅱ receptor blockers. The primary outcome was five-year major adverse cardiovascular event (MACE) (cardiac death, myocardial infarction [MI] and unplanned revascularization). Multivariable logistic regression was used to identify predictors of prescribing GDPM. Multivariable Cox regression was used to examine the relationship between GDPM and clinical outcomes. RESULTS: 10,067 patients were followed up for a median of 5.0 years (interquartile range: 4.3–5.2), 45.1% were prescribed with GDPM. Presenting with ST-segment elevation MI (adjusted OR = 3.252 [2.832–3.736]), prior MI (adjusted OR = 2.174 [1.948–2.425]), more stents implanted (adjusted OR = 1.063 [1.022–1.106]), overweight (adjusted OR = 1.136 [1.038–1.243]), obesity (adjusted OR = 1.274 [1.100–1.476]), diabetes (adjusted OR = 1.225 [1.115–1.344]), and hypertension (adjusted OR = 3.556 [3.196–3.956]) predicted the prescription of GDPM. Advanced age (adjusted OR = 0.556 [0.379–0.816]) was associated with lower prescription rate of GDPM. Patients with GDPM had lower rate of 5-year MACE (adjusted HR = 0.889 [0.808–0.978]) relative to those without GDPM. CONCLUSIONS: Despite the benefit of GDPM in improving the prognosis of CAD patients undergoing PCI, gaps still exist in GDPM prescription in real-world clinical practice. Our study determined target populations for physicians to strive to promote the application of GDPM.
format Online
Article
Text
id pubmed-8719473
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-87194732022-02-08 Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Li, Tianyu Tang, Xiaofang Song, Ying Yao, Yi Zhao, Xueyan Gao, Zhan Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Glob Heart Original Research BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-world clinical practice and to assess the effect of GDPM on clinical outcomes. DESIGN: A retrospective cohort study. METHODS: Consecutive patients admitted to Fuwai Hospital between January 2013 and December 2013 were recruited. GDPM comprised aspirin, clopidogrel, statins, β-blockers, and angiotensin-converting enzyme inhibitors/angiotensin Ⅱ receptor blockers. The primary outcome was five-year major adverse cardiovascular event (MACE) (cardiac death, myocardial infarction [MI] and unplanned revascularization). Multivariable logistic regression was used to identify predictors of prescribing GDPM. Multivariable Cox regression was used to examine the relationship between GDPM and clinical outcomes. RESULTS: 10,067 patients were followed up for a median of 5.0 years (interquartile range: 4.3–5.2), 45.1% were prescribed with GDPM. Presenting with ST-segment elevation MI (adjusted OR = 3.252 [2.832–3.736]), prior MI (adjusted OR = 2.174 [1.948–2.425]), more stents implanted (adjusted OR = 1.063 [1.022–1.106]), overweight (adjusted OR = 1.136 [1.038–1.243]), obesity (adjusted OR = 1.274 [1.100–1.476]), diabetes (adjusted OR = 1.225 [1.115–1.344]), and hypertension (adjusted OR = 3.556 [3.196–3.956]) predicted the prescription of GDPM. Advanced age (adjusted OR = 0.556 [0.379–0.816]) was associated with lower prescription rate of GDPM. Patients with GDPM had lower rate of 5-year MACE (adjusted HR = 0.889 [0.808–0.978]) relative to those without GDPM. CONCLUSIONS: Despite the benefit of GDPM in improving the prognosis of CAD patients undergoing PCI, gaps still exist in GDPM prescription in real-world clinical practice. Our study determined target populations for physicians to strive to promote the application of GDPM. Ubiquity Press 2021-12-27 /pmc/articles/PMC8719473/ /pubmed/35141130 http://dx.doi.org/10.5334/gh.812 Text en Copyright: © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Li, Tianyu
Tang, Xiaofang
Song, Ying
Yao, Yi
Zhao, Xueyan
Gao, Zhan
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title_full Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title_fullStr Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title_full_unstemmed Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title_short Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
title_sort predictors and outcomes of secondary prevention medication in patients with coronary artery disease undergoing percutaneous coronary intervention
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719473/
https://www.ncbi.nlm.nih.gov/pubmed/35141130
http://dx.doi.org/10.5334/gh.812
work_keys_str_mv AT litianyu predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT tangxiaofang predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT songying predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT yaoyi predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT zhaoxueyan predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT gaozhan predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT yangyuejin predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT gaorunlin predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT xubo predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention
AT yuanjinqing predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention